Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel–treated patients in the TRANSCEND NHL 001 trial

Chimeric antigen receptor (CAR) T-cell therapies have demonstrated high response rates in patients with relapsed/refractory large B-cell lymphoma (LBCL); however, these therapies are associated with 2 CAR T cell–specific potentially severe adverse events (AEs): cytokine release syndrome (CRS) and ne...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Adv
Asıl Yazarlar: Abramson, Jeremy S., Siddiqi, Tanya, Garcia, Jacob, Dehner, Christine, Kim, Yeonhee, Nguyen, Andy, Snyder, Sophie, McGarvey, November, Gitlin, Matthew, Pelletier, Corey, Jun, Monika P.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2021
Konular:
Immunobiology and Immunotherapy
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7993105/
https://ncbi.nlm.nih.gov/pubmed/33720336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2020003531
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller